IL0010852080 - Common Stock
NASDAQ:CGEN (12/7/2022, 1:24:50 PM)-0.02 (-1.75%)
|GICS Sector||Health Care|
|GICS Industry||Life Sciences Tools & Services|
|Earnings (Last)||11-14 2022-11-14/bmo||Earnings (Next)||02-22 2023-02-22|
|Ins Owners||N/A||Inst Owners||25.46%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Azrieli Center, 26 Harokmim St. Bldg D
CEO: Anat Cohen-Dayag
Compugen (CGEN) said its drug COM701 in dual and triple combination with Bristol-Myers Squibb's (BMY) Opdivo (nivolumab) ± BMS-986207 (anti-TIGIT) showed preliminary durable...
At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 (anti-TIGIT) demonstrated encouraging 20% overall response rate and 40% disease control...
Market factors and a company announcement helped the stock climb.
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
The company is receiving a $7.5 milestone payment from AstraZeneca for the use of one of its therapies.
Investors indicated their displeasure with the company's recent fundamentals.
Here you can normally see the latest stock twits on CGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.